NICE does not recommend ibrutinib
The National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend ibrutinib within its marketing authorisation for treating chronic lymphocytic leukaemia. A consultation on the guidance will be available on the NICE website until 23 March 2016.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200823
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com